Cellular basis of allograft rejection in vivo. V. Examination of the mechanisms responsible for the differing efficacy of monoclonal antibody to CD4+ T cell subsets in low- and high-responder rat strains

Autor: Al, Ilano, Michael McConnell, Ke, Gurley, Spinelli A, Nw, Pearce, Bm, Hall

Publikováno v: Europe PubMed Central

MRC OX35, an anti-CD4 mAb, was used to treat high responder Wistar Furth (W/F) (RT1u) and low responder DA (RT1a) rats which had been grafted with directly vascularized hearts from PVG (RT1c) rats across a full MHC plus non-MHC incompatibility. Four

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::55675285147f9f3df9b4846aebe74154
https://pubmed.ncbi.nlm.nih.gov/2572644

Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma.

Autor: Shigeta S; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Lui GYL; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Shaw R; SEngine Precision Medicine, Seattle, Washington., Moser R; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Gurley KE; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Durenberger G; SEngine Precision Medicine, Seattle, Washington.; Cure First, Seattle, Washington., Rosati R; SEngine Precision Medicine, Seattle, Washington.; Cure First, Seattle, Washington., Diaz RL; SEngine Precision Medicine, Seattle, Washington.; Cure First, Seattle, Washington., Ince TA; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, and New York Presbyterian Brooklyn Methodist Hospital, New York., Swisher EM; Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington., Grandori C; SEngine Precision Medicine, Seattle, Washington.; Cure First, Seattle, Washington., Kemp CJ; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. cjkemp@fhcrc.org.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 691-703. Date of Electronic Publication: 2021 Jan 28.

Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer.

Autor: Xu C; Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Nikolova O; Computational Biology Program, School of Medicine, Oregon Health & Science University, Portland, Oregon., Basom RS; Shared Resources, Fred Hutchinson Cancer Research Center, Seattle, Washington., Mitchell RM; Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, Washington., Shaw R; Cure First, Seattle, Washington., Moser RD; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Park H; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Gurley KE; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Kao MC; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Green CL; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Schaub FX; Cure First, Seattle, Washington., Diaz RL; Cure First, Seattle, Washington., Swan HA; Cure First, Seattle, Washington., Jang IS; Sage Bionetworks, Seattle, Washington., Guinney J; Sage Bionetworks, Seattle, Washington., Gadi VK; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington., Margolin AA; Computational Biology Program, School of Medicine, Oregon Health & Science University, Portland, Oregon., Grandori C; Cure First, Seattle, Washington., Kemp CJ; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. cjkemp@fredhutch.org., Méndez E; Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2018 Jun 15; Vol. 24 (12), pp. 2828-2843. Date of Electronic Publication: 2018 Mar 29.

Induction of Liver Tumors in Mice with N-Ethyl-N-Nitrosourea or N-Nitrosodiethylamine.

Autor: Gurley KE; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109., Moser RD; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109., Kemp CJ; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109.

Publikováno v: Cold Spring Harbor protocols [Cold Spring Harb Protoc] 2015 Oct 01; Vol. 2015 (10), pp. 941-2. Date of Electronic Publication: 2015 Oct 01.

Induction of Colon Cancer in Mice with 1,2-Dimethylhydrazine.

Autor: Gurley KE; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109., Moser RD; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109., Kemp CJ; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109.

Publikováno v: Cold Spring Harbor protocols [Cold Spring Harb Protoc] 2015 Sep 01; Vol. 2015 (9), pp. pdb.prot077453. Date of Electronic Publication: 2015 Sep 01.